Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

[1]  S. Greenberg,et al.  Microbleeds do not affect rate of cognitive decline in Alzheimer disease , 2013, Neurology.

[2]  John C. Morris,et al.  Progression of Alzheimer’s disease as measured by Clinical Dementia Rating Sum of Boxes scores , 2013, Alzheimer's & Dementia.

[3]  K. Herholz.  Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease. , 2012, Biomarkers in medicine.

[4]  W. M. van der Flier,et al.  Microbleeds do not affect rate of cognitive decline in Alzheimer disease , 2012, Neurology.

[5]  N. Relkin,et al.  The Gammaglobulin Alzheimer Partnership Study (GAP): Design, screening, enrollment and futility analysis results , 2012, Alzheimer's & Dementia.

[6]  N. Relkin,et al.  Three-year follow-up on the IVIg for Alzheimer's phase II study , 2012, Alzheimer's & Dementia.

[7]  Nick C Fox,et al.  Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis , 2012, The Lancet Neurology.

[8]  Clifford R. Jack,et al.  Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup , 2011, Alzheimer's & Dementia.

[9]  R. Green,et al.  Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study. , 2011, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[10]  Kaori Ito,et al.  Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database , 2011, Alzheimer's & Dementia.

[11]  D. Morgan.  Immunotherapy for Alzheimer’s disease , 2011, Journal of internal medicine.

[12]  B. Winblad,et al.  Alzheimer's disease: clinical trials and drug development , 2010, The Lancet Neurology.

[13]  Michael W. Weiner,et al.  Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative , 2010, NeuroImage.

[14]  K. Blennow,et al.  Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall , 2010, Clinical chemistry and laboratory medicine.

[15]  E. Masliah,et al.  Can Alzheimer disease be prevented by amyloid-β immunotherapy? , 2010, Nature Reviews Neurology.

[16]  N. Relkin,et al.  18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease , 2009, Neurobiology of Aging.

[17]  K. Blennow,et al.  Evolution of Aβ42 and Aβ40 levels and Aβ42/Aβ40 ratio in plasma during progression of Alzheimer’s disease: A multicenter assessment , 2009 .

[18]  N. Relkin.  Current State of Immunotherapy for Alzheimer’s Disease , 2008, CNS Spectrums.

[19]  R. Gold,et al.  Drug Insight: the use of intravenous immunoglobulin in neurology—therapeutic considerations and practical issues , 2007, Nature Clinical Practice Neurology.

[20]  I. Marie,et al.  Intravenous immunoglobulin‐associated arterial and venous thrombosis; report of a series and review of the literature , 2006, The British journal of dermatology.

[21]  M. Wittstock,et al.  Adverse effects of treatment with intravenous immunoglobulins for neurological diseases , 2006, Journal of Neurology.

[22]  H. Möller,et al.  Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[23]  N. Relkin,et al.  Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals , 2002, Experimental Gerontology.

[24]  D. Holtzman,et al.  Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease , 2002, Science.

[25]  Johan Gabrielsson,et al.  Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications , 2002 .

[26]  W. Oertel,et al.  Reduced levels of amyloid β-peptide antibody in Alzheimer disease , 2001, Neurology.

[27]  F. Bellavance,et al.  Tracking Cognitive Decline in Alzheimer's Disease Using the Mini-Mental State Examination: A Meta-Analysis , 2000, International Psychogeriatrics.

[28]  Weiner,et al.  Methodology for pharmacokinetic/pharmacodynamic data analysis. , 1999, Pharmaceutical science & technology today.

[29]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[30]  V. Leirer,et al.  Development and validation of a geriatric depression screening scale: a preliminary report. , 1982, Journal of psychiatric research.

[31]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.